In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Serono, Genmab end HuMax-CD4 agreement

Executive Summary

On the heels of a preclinical HuMax deal they signed earlier this year, Serono and Genmab have entered into another agreement, this time giving Serono exclusive worldwide development and commercialization rights to later-stage HuMax-CD4 for cutaneous and non-cutaneous T-cell lymphoma.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies